Patents by Inventor Yasuhiro Ikeura
Yasuhiro Ikeura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8545873Abstract: A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2, wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is ? times by mass to 4 times by mass as that of the rosin-based resin.Type: GrantFiled: March 13, 2012Date of Patent: October 1, 2013Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Publication number: 20120171278Abstract: A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2, wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is 1/3 times by mass to 4 times by mass as that of the rosin-based resin.Type: ApplicationFiled: March 13, 2012Publication date: July 5, 2012Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Yasunori TAKADA, Koji TANAKA, Yasuhiro IKEURA
-
Patent number: 8173156Abstract: An anti-inflammatory-containing plaster is provided. The anti-inflammatory-containing plaster may include, e.g., a styrene-isoprene-styrene block copolymer, a high molecular weight polyisobutylene, a low molecular weight polyisobutylene, a tackifier, a plasticizer, a dispersant, and an anti-inflammatory having a carboxyl group or a salt thereof. However, the anti-inflammatory-containing plaster does not contain L-menthol. The anti-inflammatory-containing plaster has medicament release rates of 20-64% by mass and 40-93% by mass at one hour and three hours, respectively.Type: GrantFiled: June 10, 2009Date of Patent: May 8, 2012Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasuhiro Ikeura, Miyuki Shinmura
-
Patent number: 8158145Abstract: A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2, wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is ? times by mass to 4 times by mass as that of the rosin-based resin.Type: GrantFiled: February 19, 2003Date of Patent: April 17, 2012Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Patent number: 7615237Abstract: Percutaneously absorbable preparations (preferably nonaqueous ones, particularly matrix-type patches or ointment), containing salt-form acidic drugs and characterized by being improved in the percutaneous absorbability of the drug by the incorporation of an addition salt of a basic substance therewith and by being lowly irritant to the skin; and a percutaneous absorption accelerator for salt-form acidic drugs, containing an addition salt of a basic substance.Type: GrantFiled: July 11, 2000Date of Patent: November 10, 2009Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Publication number: 20090258952Abstract: An anti-inflammatory-containing plaster is provided. The anti-inflammatory-containing plaster may include, e.g., a styrene-isoprene-styrene block copolymer, a high molecular weight polyisobutylene, a low molecular weight polyisobutylene, a tackifier, a plasticizer, a dispersant, and an anti-inflammatory having a carboxyl group or a salt thereof. However, the anti-inflammatory-containing plaster does not contain L-menthol. The anti-inflammatory-containing plaster has medicament release rates of 20-64% by mass and 40-93% by mass at one hour and three hours, respectively.Type: ApplicationFiled: June 10, 2009Publication date: October 15, 2009Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Yasuhiro Ikeura, Miyuki Shinmura
-
Patent number: 7250546Abstract: This invention provides a patch with less skin stimulation, excellent in long time store stability and heat stability and having favorable tack during use. The patch comprising a styrene-isoprene-styrene block copolymer, polyisobutylene, tackifier, plasticizer and pharmaceutically effective ingredient, in which two or more kinds of polyisobutylene of different average molecular weight are used in combination and the viscosity of the adhesive of the patch is between 1500 and 30,000 poise (at 60° C.) and the tack of the patch is from 5 to 200 g/10 mm.Type: GrantFiled: December 5, 2006Date of Patent: July 31, 2007Assignee: Hisamitsu Pharmaceuticals Co., Inc.Inventors: Kiyomi Tsuruda, Yasuhiro Ikeura
-
Publication number: 20070083139Abstract: This invention provides a patch with less skin stimulation, excellent in long time store stability and heat stability and having favorable tack during use. The patch comprising a styrene-isoprene-styrene block copolymer, polyisobutylene, tackifier, plasticizer and pharmaceutically effective ingredient, in which two or more kinds of polyisobutylene of different average molecular weight are used in combination and the viscosity of the adhesive of the patch is between 1500 and 30,000 poise (at 60° C.) and the tack of the patch is from 5 to 200 g/10 mm.Type: ApplicationFiled: December 5, 2006Publication date: April 12, 2007Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventors: Kiyomi Tsuruda, Yasuhiro Ikeura
-
Patent number: 7153522Abstract: Percutaneous sorbefacients comprising hexylene glycol and 1-menthol, more particularly, percutaneous sorbefacients for female hormones or derivatives thereof; and preparations for percutaneous absorption which comprise a styrene/isoprene/styrene block copolymer and/or polyisobutylene, a softener and a tackifier as the base components, hormones, in particular, follicle hormone and/or luteal hormone as the drug component and hexylene glycol and 1-menthol as a sorbefacient.Type: GrantFiled: October 14, 1999Date of Patent: December 26, 2006Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasuhiro Ikeura, Masayoshi Maki
-
Patent number: 6991095Abstract: Packaged patch (10) according to the invention comprises patch (2) situated in space (4) inside patch package (3) composed of laminated packaging material (1), and its edges are sealed. Laminated packaging material (1) comprises hygroscopic material layer (13) made of LDPE containing 20–40 wt % of an inorganic filler, situated between moisture-permeable material layer (14) made of LDPE and having a moisture permeability of 40–120 g/m2/day and a screen material layer which blocks penetration of moisture, etc. and is composed of HDPE layer (12) and aluminum foil (11). The saturation hygroscopicity of laminated packaging material (1) is 2–30 g/m2 under atmosphere conditions with a temperature of 25° C. and a relative humidity of 75%. This construction sufficiently reduces the effect of moisture on a drug in patch (2) and allows patch (2) to be held in a stable state for prolonged periods, while also improving the economy and handleability of patch package (3).Type: GrantFiled: June 30, 2000Date of Patent: January 31, 2006Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Shinji Yamasoto, Yasuhiro Ikeura
-
Patent number: 6924410Abstract: A patch has a backing which has been subjected to an ultraviolet-screening processing, the backing usually being of one layer. The ultraviolet-screening processing usually uses an organic ultraviolet absorbent and/or an inorganic ultraviolet-screening agent. The patch can contain in its base a medicine of poor photo-stability and a non-steroidal anti-inflammatory analgesic.Type: GrantFiled: March 13, 2001Date of Patent: August 2, 2005Assignee: Hisamitsu Pharmaceutical Co., Ltd.Inventors: Kiyomi Tsuruda, Yasuhiro Ikeura
-
Publication number: 20050129748Abstract: A transdermal patch comprising a backing 2 and an adhesive layer 3 laminated on the backing 2, wherein the adhesive layer 3 comprises a rosin-based resin and petroleum resin as a tackifier, the total compounding amount of the rosin-based resin and the petroleum resin is in a range of 15% by mass to 50% by mass, and compounding amount of the petroleum resin is ? times by mass to 4 times by mass as that of the rosin-based resin.Type: ApplicationFiled: February 19, 2003Publication date: June 16, 2005Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Patent number: 6844007Abstract: A plaster comprising a styrene-isoprene-styrene block copolymer 10-40 wt %, a rosin-based resin 5-30 wt %, a plasticizer 20-70 wt %, polyisobutylene 6-40 wt %, an antioxidant 0.1-5 wt %, and felbinac as a medicinally effective component 1.1-10 wt %, wherein the plaster does not contain crotamiton which is a solubilizer for the felbinac, the felbinac is uniformly dispersed in a semi-solubilized state in the plaster, wherein solubilized felbinac and microcrystalline felbinac coexist in the plaster, and a thickness of the plaster is 50-300 ?m.Type: GrantFiled: June 27, 2003Date of Patent: January 18, 2005Assignee: Hisamitsu Pharmaceutical Co., Ltd.Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Patent number: 6833138Abstract: A plaster comprising a styrene-isoprene-styrene block copolymer 10-40 wt %, a rosin-based resin 5-30 wt %, a plasticizer 20-70 wt %, polyisobutylene 6-40 wt %, an antioxidant 0.1-5 wt %, and felbinac as a medicinally effective component 1.1-10 wt %, wherein the plaster does not contain crotamiton which is a solubilizer for the felbinac, the felbinac is uniformly dispersed in a semi-solubilized state in the plaster, wherein solubilized felbinac and microcrystalline felbinac coexist in the plaster, and a thickness of the plaster is 50-300 &mgr;m.Type: GrantFiled: June 27, 2003Date of Patent: December 21, 2004Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Publication number: 20040146548Abstract: It is intended to provide percutaneously absorbable patches having an improved percutaneous absorbability of an anti-inflammatory agent in the form of a salt and an improved stability. Namely, percutaneously absorbable patches having an adhesive base layer which contains an anti-inflammatory agent in the form of a salt, an ammonium salt compound, an absorption enhancer and/or a solubilizer.Type: ApplicationFiled: November 25, 2003Publication date: July 29, 2004Inventors: Yasunori Takada, Koji Tanaka, Tomonori Kurita, Yasuhiro Ikeura
-
Publication number: 20040086555Abstract: A plaster comprising a styrene-isoprene-styrene block copolymer 10-40 wt %, a rosin-based resin 5-30 wt %, a plasticizer 20-70 wt %, polyisobutylene 6-40 wt %, an antioxidant 0.1-5 wt %, and felbinac as a medicinally effective component 1.1-10 wt %, wherein the plaster does not contain crotamiton which is a solubilizer for the felbinac, the felbinac is uniformly dispersed in a semi-solubilized state in the plaster, wherein solubilized felbinac and microcrystalline felbinac coexist in the plaster, and a thickness of the plaster is 50-300 &mgr;m.Type: ApplicationFiled: June 27, 2003Publication date: May 6, 2004Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Publication number: 20040086554Abstract: A plaster comprising a styrene-isoprene-styrene block copolymer 10-40 wt %, a rosin-based resin 5-30 wt %, a plasticizer 20-70 wt %, polyisobutylene 6-40 wt %, an antioxidant 0.1-5 wt %, and felbinac as a medicinally effective component 1.1-10 wt %, wherein the plaster does not contain crotamiton which is a solubilizer for the felbinac, the felbinac is uniformly dispersed in a semi-solubilized state in the plaster, wherein solubilized felbinac and microcrystalline felbinac coexist in the plaster, and a thickness of the plaster is 50-300 &mgr;m.Type: ApplicationFiled: June 27, 2003Publication date: May 6, 2004Applicant: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Publication number: 20040039356Abstract: It is intended to provide compositions for external preparations (in particular, adhesive preparations) which are excellent in the skin permeability of the active ingredient, make it possible to give a compact preparation size and exert relieved skin irritation in percutaneous preparations, etc. to be used in, for example, hormone substitution therapy. Namely, compositions for external preparation which contain a vegetable oil and polyvinyl pyrrolidone as a sorbefacient and/or a dissolution aid; and adhesive preparations containing these compositions.Type: ApplicationFiled: April 14, 2003Publication date: February 26, 2004Inventors: Masayoshi Maki, Yasuhiro Ikeura
-
Patent number: 6620430Abstract: A plaster comprising a styrene-isoprene-styrene block copolymer 10-40 wt %, a rosin-based resin 5-30 wt %, a plasticizer 20-70 wt %, polyisobutylene 6-40 wt %, an antioxidant 0.1-5 wt %, and felbinac as a medicinally effective component 1.1-10 wt %, wherein the plaster does not contain crotamiton which is a solubilizer for the felbinac, the felbinac is uniformly dispersed in a semi-solubilized state in the plaster, wherein solubilized felbinac and microcrystalline felbinac coexist in the plaster, and a thickness of the plaster is 50-300 &mgr;m.Type: GrantFiled: May 18, 2001Date of Patent: September 16, 2003Assignee: Hisamitsu Pharmaceutical Co., Inc.Inventors: Yasunori Takada, Koji Tanaka, Yasuhiro Ikeura
-
Publication number: 20030149383Abstract: An antiinflammatory-containing plaster comprising 5-40% by mass of a styrene-isoprene-styrene block copolymer, 1-25% by mass of a high molecular weight polyisobutylene, 0.5-24% by mass of a low molecular weight polyisobutylene, 3-50% by mass of a tackifier, 20-70% by mass of a plasticizer, 0.01-7% by mass of a dispersant, and 0.1-8% by mass of an antiinflammatory having a carboxyl group or a salt thereof, but which contains no L-menthol, wherein the medicament release rate at one hour after the start of test is 20-64% by mass and the medicament release rate at three hours after the start of test is 40-93% by mass according to the water-releasing test using a rotating cylinder described in the release test as prescribed in United State Pharmacopoeia.Type: ApplicationFiled: October 18, 2002Publication date: August 7, 2003Inventors: Yasuhiro Ikeura, Miyuki Shinmura